Recordati steps towards a promising future with the approval of an ambitious Three-Year Financial Plan for 2025-2027

Recordati, a leading pharmaceutical entity, has revealed an ambitious three-year plan for the 2025-2027 period. This strategic move, designed to project the company towards a prosperous future, has received firm approval from the Board of Directors of Recordati S.p.A.

This plan builds on Recordati’s existing strategy of driving organic growth across both Primary & Specialty Care and Rare Diseases by tapping into new business development opportunities and strategic mergers and acquisitions. The company also aims to continue exploring targeted pipeline opportunities. The focus will be on low-risk lifecycle management programs for new indications and geographic expansion, whilst maintaining stellar sector-leading margins.

An upward sales target for the product Isturisa® following its favorable label expansion by the U.S. FDA, and the recent approval of Signifor® LAR in China, bolsters the company’s strategic plan. The financial plan also targets an EBITDA between €1,140 and €1,225 million. This margin of ≥38% will be powered by operative leverage and a diverse product mix, demonstrating the corporation’s astute financial management coupled with strategic manoeuvres.

Appropriately backed by Recordati’s progressive dividend policy, the plan charts a path of stability, standing strong amidst the uncertainties of the economic climate. Chief Executive Officer of Recordati, Rob Koremans voiced confidence in the company’s ability to leverage its highly diversified portfolio to sustain the business momentum and capitalize on growth opportunities.